Evolution of herd SARS-CoV-2 humoral immunity in the Republic of Belarus

Author:

Popova Anna Yu.ORCID,Smirnov Viacheslav S.ORCID,Egorova Svetlana A.ORCID,Tarasenko Alexander A.ORCID,Dashkevich Alla M.ORCID,Milichkina Angelica M.ORCID,Skuranovich Angela L.ORCID,Drozd Irina V.ORCID,Glinskaya Irina N.ORCID,Zueva Elena V.ORCID,Samoilovich Elena O.ORCID,Ivanov Valery A.ORCID,Ramsay Edward SmithORCID,Gubanova Alexandra V.ORCID,Drobyshevskaya Victoria G.ORCID,Zhimbaeva Oyuna B.ORCID,Petrova Olga A.ORCID,Razumovskaya Alexandra P.ORCID,Karaban Inna A.ORCID,Amvrosyeva Tamara V.ORCID,Shmeleva Natalya P.ORCID,Rubanik Lyudmila V.ORCID,Dronina Alina M.ORCID,Totolian Areg A.ORCID

Abstract

Background. The course of the COVID-19 epidemic process depends on population immunity which prevents pathogen spread. Aim: to study an evolution of SARS-CoV-2 humoral immunity in the Belarusian population rela- tive to COVID-19 pandemic dynamics. Materials and methods. The work was carried out according to a methodology for assessing herd immunity developed by Rospotrebnadzor (Russia) and the Belarusian Ministry of Health involving the St. Petersburg Pasteur Institute (SPPI) by taking into account the WHO recommendations. The study was approved by the Bioethics Committee of Belarus and the SPPI Bioethics Committee. Participant selection was carried out by ques- tionnaire using a cloud (internet server) service. To monitor herd immunity, a cohort of 4661 subjects (involved at all stages of seromonitoring) was formed from the total volunteer group. Study subjects were randomized into groups based on age (117, 1829, 3039, 4049, 5059, 6069, 70+ years), geographic region, and occupation. For the detection of antibodies (Abs) against SARS-CoV-2 nucleocapsid (Nc) and S glycoprotein receptor-binding domain (RBD), rel- evant assay systems were used according to the manufacturers instructions. A four-stage study was conducted according to a unified scheme. Results. At stage 1 (pandemic month 15), herd immunity was mainly accounted for by Nc+RBD+ Ab status alone. By stage 2 (4 months later), its specific proportion decreased by 1.2-fold, whereas percentage of subjects solely bearing RBD-specific Abs increased by 1.7-fold. At stages 3 and 4 (9 and 19 months after the onset) vs. stage 2, percent- age of subjects with RBD+Nc decreased by 3.5%; the proportion of persons with Nc+RBD Abs increased by 1.5-fold. The most important contributor in herd immunity turned out to be due to population vaccination, with coverage reaching 70% by stage 4. Among vaccines, compared with whole-virion, inactivated BIBP-CorV vaccine the Sputnik V and Sputnik Light vector were used most often. Conclusion. The evolution of herd SARS-CoV-2 humoral immunity included a series of changes in circulating Ab levels (Nc, RBD). The hybrid immunity formed helped to reduce the incidence of COVID-19 to sporadic level.

Publisher

SPb RAACI

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference47 articles.

1. Methodology for assessing herd immunity to the SARS-CoV-2 virus in the context of the COVID-19 pandemic

2. Смирнов В.С., Зарубаев В.В., Петленко С.В. Биология возбудителей и контроль гриппа и ОРВИ. СПб.: Гиппократ, 2020. 336 c. [Smirnov V.S., Zarubaev V.V., Petlenko S.V. Biology of pathogens and control of influenza and acute respiratory viral infection. Saint Petersburg : Hippocrates, 2020. 336 c. (In Russ.)]

3. History of investigation and current classification of coronaviruses (Nidovirales: Coronaviridae)

4. Individual and network characteristic associated with hospital-acquired Middle East Respiratory Syndrome coronavirus

5. Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3